Anticipated revenues of Jakafi between $1,350-$1,400 million
Posted: Wed May 09, 2018 7:01 pm
All of this or a substantial part of it just waiting for Imet…
Incyte (INCY) Incurs Loss in Q1, Revenues Miss Estimates
May 1, 2018
Quarterly revenues were $382.2 million, up 30% year over year. The reported figure, however, missed the Zacks Consensus Estimate of $382.9 million.
Jakafi sales grew 25%, year over year to $313.7 million driven by strong patient demand.
2018 Outlook
The company continues to expect Jakafi revenues in the range of $1,350-$1,400 million.
https://finance.yahoo.com/news/incyte-i ... 07228.html
Incyte (INCY) Incurs Loss in Q1, Revenues Miss Estimates
May 1, 2018
Quarterly revenues were $382.2 million, up 30% year over year. The reported figure, however, missed the Zacks Consensus Estimate of $382.9 million.
Jakafi sales grew 25%, year over year to $313.7 million driven by strong patient demand.
2018 Outlook
The company continues to expect Jakafi revenues in the range of $1,350-$1,400 million.
https://finance.yahoo.com/news/incyte-i ... 07228.html